Eagle Hitomi Technology-B (02251) announced interim results. Shareholders' losses amounted to 488.52 million yuan, an increase of 2820% over the previous year

According to the Zhitong Finance App, Eagle Hitomi Technology-B (02251) announced the 2026 interim results, with revenue of 67.291,000 yuan, a year-on-year decrease of 19.6%; loss attributable to owners of the parent company was 488.52 million yuan, an increase of 2820% over the previous year; and a basic loss of 0.48 yuan per share.

Losses during the period were mainly due to (i) a decline in revenue due to the implementation of stricter agent selection policies and the tightening of credit period policies; (ii) increased investment in R&D and clinical trials: increased investment in R&D, computing power, and medical data governance of AI agents in various product lines, promoted multi-center clinical, device registration and compliance commercialization, and increased R&D and clinical expenses; (iii) the PBM-AI myopia prevention and control business was expanding and cultivating: the number of partner stores, users and calling models increased, market, medical services, store deployment and operation C End of eye Investment in health marketing operations has increased, and sector revenue contributions and scale effects have not yet been released; (iv) exchange rate changes have also had a certain impact on the Group's financial situation. During the reporting period, the Group relied on self-developed multi-language models to empower the middle and back office, reduce costs and increase efficiency, thereby offsetting some of these pressures.